ThromboGenics Raises EUR 0.6 Million from the Exercise of Warrants

Leuven, Belgium - October 9, 2009 - ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on innovative medicines for eye disease, vascular disease and cancer, today announces that it has raised EUR 0.6 million as the result of the exercise of warrants by a number of the Company's employees. The 90.000 shares created as a result of this warrant exercise are now listed on Euronext Brussels. Following this
transaction, ThromboGenics now has 26.417.789 shares outstanding.

For further information please contact:
ThromboGenics
Chris Buyse, CFO
Tel: + 32 16 75 13 10
chris.buyse@thrombogenics.com

Citigate Dewe Rogerson
Amber Bielecka/ David Dible/ Nina Enegren
Tel: +44 (0) 207 638 95 71
amber.bielecka@citigatedr.co.uk

About ThromboGenics
ThromboGenics is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The
Company's lead product microplasmin is in Phase III clinical development for the nonsurgical treatment of back of the eye diseases. Microplasmin is also being evaluated in
Phase II clinical development for additional vitreoretinal conditions. In addition, ThromboGenics is developing novel antibody therapeutics in collaboration with BioInvent
International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB- 403 (anti-PlGF) for cancer.
ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed
at these institutions. ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on Eurolist by Euronext Brussels under the symbol THR.

More information is available at www.thrombogenics.com